TerrAscend Corp.
For the period ended Apr 28, 2025. Filed Apr 28, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Apr 28, 2025 · Filed Apr 28, 2025
Contents
Director Information
The following table sets forth information about each Director Nominee, including (i) his or her name, age, and province or state and country of residence, (ii) the period during which each has served as a director, (iii) memberships on committees of the Board, (iv) present principal occupation, business or employment, and (v) the number of Common Shares of the Corporation or any of its subsidiaries beneficially owned, or controlled or directed, directly or indirectly.
Information regarding the number of Common Shares beneficially owned, or controlled or directed, directly or indirectly, by the Director Nominees, not being within the knowledge of the Corporation, is based upon information furnished by the applicable Director Nominee and is as at the date hereof.
| Name, Age, Province or State and Country of Residence | Principal Occupation | Current Position(s) with the Corporation | Director Since | Number of Common Shares Beneficially Owned, or Controlled or Directed, Directly or Indirectly |
|---|---|---|---|---|
| Craig Collard, 59North Carolina,United Sates | Chief Executive Officer and Director, Heron Therapeutics | Lead Independent Director Chair of the Nominating and Corporate Governance Committee Member of the Audit Committee and Compensation Committee | December 6, 2018 | 640,885 Common Shares(1) |
| Kara DioGuardi, 54Connecticut, United States | Co-Founder, Arthouse Entertainment | DirectorMember of Compensation CommitteeMember of Nominating and Corporate Governance Committee | March 3, 2022 | 272,367 Common Shares (2) |
| Name, Age, Province or State and Country of Residence | Principal Occupation | Current Position(s) with the Corporation | Director Since | Number of Common Shares Beneficially Owned, or Controlled or Directed, Directly or Indirectly |
|---|---|---|---|---|
| Ira Duarte, 56North Carolina, United States | Chief Financial Officer, Heron Therapeutics | DirectorChair of the Audit CommitteeMember of Nominating and Corporate Governance Committee | December 2, 2022 | 224,277 Common Shares (3) |
| Ed Schutter, 73 Georgia, United States | Director | Director Chair of the Compensation Committee | November 2, 2020 | 1,547,767 Common Shares (4) |
| Jason Wild, 52Florida,United States | President and Chief Investment Officer, JW Asset Management, LLC | Director, Chairman of the Board, Executive Chairman | December 8, 2017 | 90,991,236 Common Shares (5) |
(1)
Mr. Collard also owns 150,000 Options to purchase Common Shares pursuant to the Stock Option Plan (as defined below) and has additional economic exposure to the Corporation’s securities through a non-controlling investment in one of the entities controlled by Jason Wild that has a significant investment in the Corporation.
(2)
Ms. DioGuardi has additional economic exposure to the Corporation’s securities through a non-controlling investment in one of the entities controlled by Jason Wild that has a significant investment in the Corporation.
(3)
Ms. Duarte has additional economic exposure to the Corporation’s securities through a non-controlling investment in one of the entities controlled by Jason Wild that has a significant investment in the Corporation.
(4)
Mr. Schutter has economic exposure to the Corporation’s securities through a non-controlling investment in one of the entities controlled by Jason Wild that has a significant investment in the Corporation. Mr. Schutter also owns $2,000,000 principal amount of convertible debentures of the Corporation.
(5)
Mr. Wild controls 3,251,924 Common Shares held by Jason Wild personally; 101,825 Common Shares held by Howard Wild 2012 Grandchildren’s Trust; 159,984 Common Shares held by Insight Wellness Fund, LLC; 2,499,854 Common Shares held by JW Growth Fund, LLC; 50,621,892 Common Shares held by JW Partners, LP; 12,605,280 Common Shares held by JW Select Investments, LP; 21,643,277 Common Shares held by JW Opportunities Fund LLC; and 107,200 Common Shares held by Wild Family Foundation. Mr. Wild also controls 3,000 Preferred Shares held by JW Opportunities Fund, LLC.; and 7,000 Preferred Shares held by JW Partners, LP. Mr. Wild also controls 50,000 Common Share warrants held personally; 33,334 Common Share warrants held by Howard Wild 2012 Grandchildren’s Trust; and 316,667 Common Share warrants held by JW Growth Fund, LLC. Mr. Wild also owns 1,200,000 Options to purchase Common Shares pursuant to the Stock Option Plan (as defined below).
Director Biographies
The following are brief profiles of our Director Nominees, including a description of each individual’s principal occupation within the past five years.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.